Influence of cardiopulmonary resuscitation on levels of tumour markers

European Journal of Cancer Care

Volumn 15, Issue 3, 2006, Pages 252-256

  Berent, R ^a   Auer, J ^a   Porodko, M ^a   Lamm, G ^a   Weber, T ^a   Wimmer, E ^a   Seier, J ^a   Aspock G ^a   Eber, B ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cardiopulmonary resuscitation; Management; Tumour markers

Indexed keywords

ALPHA FETOPROTEIN; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; MUCIN 1; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; RESUSCITATION;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; CA-15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARDIOPULMONARY RESUSCITATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; MUCIN-1; PROSTATE-SPECIFIC ANTIGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 33745908882     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/j.1365-2354.2005.00648.x     Document Type: Article

References (21)

1. Adrie C., Laurent I., Monchi M., Cariou A., Dhainaou J.F. & Spaulding C. (2004) Postresuscitation disease after cardiac arrest: a sepsis-like syndrome? Current Opinion in Critical Care 10, 208-212.
2. Bates S.E. (1991) Clinical applications of serum tumor markers. Annals of Internal Medicine 115, 623-638.
3. Cacoub P., Le Thi H.D., Wechsler B., Chapelon C., Auperin A., Gandjbakch I., Piette J.C. & Godeau P. (1990) Chronic constrictive pericarditis responsible for an increase of CA 125 levels. Two cases. Presse Medicine 19, 1712-1714.
4. Carney W.P., Neumann R., Lipton A., Leitzel K., Ali S. & Price C.P. (2004) Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer. Clinics of Breast Cancer 5, 105-116.
5. Diegeler A., Tarnok A., Rauch T., Haberer D., Falk V., Battellini R., Autschbach R., Hambsch J., Schneider P. & Mohr F.W. (1998) Changes of leukocyte subsets in coronary artery bypass surgery: cardiopulmonary bypass versus 'off-pump' techniques. Thoracic and Cardiovascular Surgery 46, 327-332.
6. Downing S.W. & Edmunds L.H., Jr (1992) Release of vasoactive substances during cardiopulmonary bypass. The Annals of Thoracic Surgery 54, 1236-1243.
7. Duffy M.J. (2001) Clinical uses of tumor markers: a critical review. Critical Reviews of Clinical Laboratory Science 38, 225-262.
8. Feero P., Nickel J.C. & Brown P. (1990) Prostatic infarction associated with aortic and iliac aneurysm repair. Journal of Urology 143, 367-368.
9. Glenski W.J., Malek R.S. & Myrtle J.F. (1992) Sustained, substantially increased concentration of prostate-specific antigen in the absence of prostatic malignant disease: an unusual clinical scenario. Mayo Clinic Proceedings 67, 249-252.
10. Hagood P.G., Parra R.O. & Rauscher J.A. (1994) Nontraumatic elevation of prostate specific antigen following cardiac surgery and extracorporeal cardiopulmonary bypass. Journal of Urology 152, 2043-2045.
11. Jennett B. & Bond M. (1975) Assessment of outcome after severe brain damage: a practical scale. Lancet 1, 480-484.
12. Jorgensen E.O. (1998) Neurological and circulatory outcome of cardiopulmonary resuscitation in progress: influence of pre-arrest and arrest factors. Resuscitation 36, 45-49.
13. Koh K.K., In H.H., Lee K.H., Kim E.J., Cho C.H., Cho S.K., Kim S.S., Cho S.S., Baek W.K., Jin S.H., Ju Y.C., Kim J.J., Park C.S., Nam H.S. & Lee Y.H. (1997) New scoring system using tumor markers in diagnosing patients with moderate pericardial effusions. International Journal of Cardiology 61, 5-13.
14. Koller-Strametz J., Fritzer M., Gwechenberger M., Geppert A., Heinz G., Haumer M., Koreny M., Maurer G. & Siostrzonek P. (2000) Elevation of prostate-specific markers after cardiopulmonary resuscitation. Circulation 102, 290-293.
15. Le Thi Huong D., Wechsler B., Piette J.C., de Gennes C., Cabane J., Bletry O. & Godeau P. (1988) Wegener's granulomatosis in elderly subjects. 37 cases. Presse Medicine 17, 2379-2382.
16. Nagele H., Bahlo M., Klapdor R., Schaeperkoetter D. & Rodiger W. (1999a) CA 125 and its relation to cardiac function. American Heart Journal 137, 1044-1049.
17. Nagele H., Bahlo M., Klapdor R. & Rodiger W. (1999b) Fluctuations of tumor markers in heart failure patients pre- and post-heart transplantation. Anticancer Research 19, 2531-2534.
18. Oesterling J.E. (1991) Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. Journal of Urology 145, 907-923.
19. Ruibal Morell A. (1992) CEA serum levels in non-neoplastic disease. International Journal of Biological Markers 7, 160-166.
20. Stamey T.A., Yang N. & Hay A.R. (1987) Pro state-specific antigen as a serum marker for adenocarcinoma of the prostate. New England Journal of Medicine 317, 909-916.
21. Westaby S. (1987) Organ dysfunction after cardiopulmonary bypass. A systemic inflammatory reaction initiated by the extracorporeal circuit. Intensive Care Medicine 13, 89-95.